An investigation on behalf of investors in NASDAQ:INFI shares over potential wrongdoing at Infinity Pharmaceuticals Inc. was announced and NASDAQ:INFI stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/22/2016 -- An investigation on behalf of current long-term investors in NASDAQ:INFI shares was announced over potential breaches of fiduciary duties by certain officers and directors at Infinity Pharmaceuticals.
Investors who purchased shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and currently hold any of those NASDAQ:INFI shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Infinity Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Infinity Pharmaceuticals Inc. reported that its annual Total Revenue declined from $165 million in 2104 to $109.07 million in 2015 and that its Net Loss increased from $17.42 million in 2014 to $128.38 million in 2015. Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) declined from $17.78 per share in December 2014 to as low as $1.24 per share on June 14, 2016.
On June 21, 2016, NASDAQ:INFI shares closed at $1.32 per share.
Those who purchased shares of Infinity Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego